Benjamin A Rogers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/725009/publications.pdf

Version: 2024-02-01

30 papers 2,829 citations

16 h-index 29 g-index

30 all docs 30 docs citations

30 times ranked

4265 citing authors

#	Article	IF	CITATIONS
1	Potential interventions for an antimicrobial stewardship bundle for Escherichia coli bacteraemia. International Journal of Antimicrobial Agents, 2021, 57, 106301.	1.1	1
2	Incidental mucocutaneous cytomegalovirus detection and its predictive value for systemic disease. Pathology, 2020, 52, 478-482.	0.3	1
3	A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards. Trials, 2020, 21, 92.	0.7	6
4	Mycobacterium tuberculosis: <scp>A</scp> ctive disease and latent infection in a renal transplant cohort. Nephrology, 2019, 24, 569-574.	0.7	10
5	Case Reports: Late Emergence of Cutaneous Leishmaniasis in an Immunocompromised Patient in a Non-Endemic Setting. American Journal of Tropical Medicine and Hygiene, 2019, 100, 115-116.	0.6	2
6	Fosfomycin: what was old is new again. Internal Medicine Journal, 2018, 48, 1425-1429.	0.5	5
7	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	3.8	538
8	Local acquisition and nosocomial transmission of Klebsiella pneumoniae harbouring the blaNDMâ€1 gene in Australia. Medical Journal of Australia, 2015, 202, 270-271.	0.8	5
9	Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New Zealand. International Journal of Antimicrobial Agents, 2015, 45, 351-358.	1.1	18
10	Reply to Bonten and Mevius. Clinical Infectious Diseases, 2015, 60, 1867-1868.	2.9	O
10	Reply to Bonten and Mevius. Clinical Infectious Diseases, 2015, 60, 1867-1868. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	2.9	57
	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for		
11	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24. Do Human Extraintestinal Escherichia coli Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. Clinical Infectious Diseases, 2015, 60,	0.7	57
11 12	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24. Do Human Extraintestinal Escherichia coli Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. Clinical Infectious Diseases, 2015, 60, 439-452. Global dissemination of a multidrug resistant <i>Escherichia coli /i> clone. Proceedings of the</i>	0.7	209
11 12 13	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24. Do Human Extraintestinal Escherichia coli Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. Clinical Infectious Diseases, 2015, 60, 439-452. Global dissemination of a multidrug resistant <i>Escherichia coli</i> National Academy of Sciences of the United States of America, 2014, 111, 5694-5699. Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in	0.7 2.9 3.3	57 209 498
11 12 13	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24. Do Human Extraintestinal Escherichia coli Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. Clinical Infectious Diseases, 2015, 60, 439-452. Global dissemination of a multidrug resistant <i>Escherichia coli</i> <ir> Clobal dissemination of Sciences of the United States of America, 2014, 111, 5694-5699. Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries. Antimicrobial Agents and Chemotherapy, 2014, 58, 2126-2134. Predictors of use of infection control precautions for multiresistant gram-negative bacilli in Australian hospitals: Analysis of a national survey. American Journal of Infection Control, 2014, 42,</ir>	0.7 2.9 3.3	57 209 498 33
11 12 13 14	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24. Do Human Extraintestinal Escherichia coli Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. Clinical Infectious Diseases, 2015, 60, 439-452. Global dissemination of a multidrug resistant <i>Escherichia coli /i> clone. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5694-5699. Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries. Antimicrobial Agents and Chemotherapy, 2014, 58, 2126-2134. Predictors of use of infection control precautions for multiresistant gram-negative bacilli in Australian hospitals: Analysis of a national survey. American Journal of Infection Control, 2014, 42, 963-969. Co-selection may explain high rates of ciprofloxacin non-susceptible Escherichia coli from retail poultry reared without prior fluoroquinolone exposure. Journal of Medical Microbiology, 2013, 62,</i>	0.7 2.9 3.3 1.4	57 209 498 33

#	Article	IF	CITATIONS
19	Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy: New Challenges in the Era of Multidrug-Resistant Escherichia coli. Clinical Infectious Diseases, 2013, 57, 267-274.	2.9	127
20	Treatment Options for New Delhi Metallo-Beta-Lactamase-Harboring Enterobacteriaceae. Microbial Drug Resistance, 2013, 19, 100-103.	0.9	71
21	Vancomycin therapeutics and monitoring: a contemporary approach. Internal Medicine Journal, 2013, 43, 110-119.	0.5	57
22	Uropathogenic Escherichia coli Mediated Urinary Tract Infection. Current Drug Targets, 2012, 13, 1386-1399.	1.0	97
23	An oral carbapenem, but only now intravenous penicillin: the paradox of Japanese antimicrobials. International Journal of Infectious Diseases, 2012, 16, e830-e832.	1.5	4
24	Prolonged carriage of resistant E. coli by returned travellers: clonality, risk factors and bacterial characteristics. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 2413-2420.	1.3	48
25	Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Internal Medicine Journal, 2011, 41, 441-449.	0.5	176
26	Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. Journal of Antimicrobial Chemotherapy, 2011, 66, 1-14.	1.3	629
27	Country-to-Country Transfer of Patients and the Risk of Multi-Resistant Bacterial Infection. Clinical Infectious Diseases, 2011, 53, 49-56.	2.9	150
28	How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrugâ€Resistant Bacterial Infection. Clinical Infectious Diseases, 2010, 51, 1245-1247.	2.9	28
29	Imported West Nile virus encephalitis in an Israeli tourist. Medical Journal of Australia, 2009, 191, 232-234.	0.8	8
30	Methicillin Resistant Staphylococcus aureus Endocarditis in an Australian Tertiary Hospital: 1991–2006. Heart Lung and Circulation, 2009, 18, 208-213.	0.2	11